Michael Gibney
Senior Editor & Writer | LinkedInMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
237 articles by Michael Gibney
-
AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Feb. 27, 2025 -
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Feb. 25, 2025 -
Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Feb. 20, 2025 -
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
Feb. 13, 2025 -
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
Feb. 11, 2025 -
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
Feb. 6, 2025 -
Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid
Feb. 4, 2025 -
RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing
Jan. 30, 2025 -
Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt
Jan. 28, 2025 -
J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?
Jan. 23, 2025 -
By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years
Jan. 16, 2025 -
Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?
Jan. 14, 2025 -
After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
Jan. 9, 2025 -
How pharma was instrumental in President Jimmy Carter’s global health efforts
Jan. 3, 2025 -
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market
Dec. 19, 2024 -
Maternal mortality trends remain dire — and researchers face an uphill battle to solve them
Dec. 17, 2024 -
Regeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
Dec. 12, 2024 -
GSK’s multiple myeloma ADC Blenrep was pulled from the market. Now, it’s poised for a comeback.
Dec. 10, 2024 -
How Astellas juggles the moving parts of cancer precision medicine development
Dec. 5, 2024 -
How Alexion markets a rare disease drug by ‘starting with the end in mind’
Dec. 3, 2024 -
An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Nov. 26, 2024 -
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
Nov. 21, 2024 -
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
Nov. 19, 2024 -
Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
Nov. 14, 2024 -
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Nov. 7, 2024